Institutional investors purchased a net $3.9 million shares of THRX during the quarter ended March 2013. This may signal that the smart money is gaining interest in this company as the 76.63% of the shares outstanding that institutional investors hold is among the lowest in the Biotechnology industry.
| Mutual fund holders | 41.65% |
| Individual stakeholders | 38.01% |
| Other institutional | 34.99% |